Future Price to Earnings: Sarepta Therapeutics (SRPT)

Sarepta Corp - graphic logo of issuer SRPT

Will the risks of failed tests and therapy payment complexities impact capitalization? The forward P/E multiple of the business provides the answer, with the current value standing at 156.50. Sarepta Therapeutics, Inc. (SRPT) leads the treatment of Duchenne muscular dystrophy, leveraging its status as an industry pioneer. High customer loyalty ensures a steady cash flow, completely eliminating the probability of a funding shortfall.

sarepta.com - SRPT Market Cap to Future Earnings Ratio (period 07/04/2022 - 11/18/2026)

Financial and market metric breakdowns for Sarepta (SRPT)

- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
Summary company analysis:Sarepta Therapeutics Inc
Product sample of sarepta.com

Forward P/E determines business value through the ratio of the current share price to the projected earnings per share for the year. By analyzing the expected P/E multiple of a company, an investor identifies the extent of the premium paid for future earnings. The calculation is based on analysts' consensus forecasts for net income. For Sarepta Therapeutics, Inc. (SRPT), this indicator reflects market confidence in the commercialization of gene therapy. High values here are justified by unique patents and strict FDA control.

Direct competitors

Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (CRISPR Therapeutics Corp)|WGS: Forward P/E Multiple|Projected Price to Earnings Ratio Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Forward P/E Multiple|twistbioscience.com (TWST) - Market Cap to Projected Earnings|Forward P/E Multiple TXG|NTLA (Intellia) - Future Price to Earnings Multiple|Future Price to Earnings Stoke STOK|BioLife (BLFS) - Projected Price to Earnings Ratio|wavelifesciences.com - Forward P/E Multiple|Price to Expected Earnings Ratio MAZE|SION: Forward P/E Multiple|PRME - Market Cap to Projected Earnings|Projected Price to Earnings TSHA|QURE - Forward Price to Earnings Multiple|Forward P/E Multiple MGTX|Market Cap to Projected Earnings regenxbio.com|Forward P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Future Earnings Ratio|PACB - Future Price to Earnings|Benitec (BNTC) - Projected Price to Earnings|DSGN: Forward P/E Multiple|RCKT: Market Cap to Future Earnings Ratio|FDMT (4D Molecular Therapeutics, Inc.) - Forward P/E Multiple|lexeotx.com (LXEO) - Market Cap to Projected Earnings|Forward P/E Multiple KRRO|Projected Price to Earnings Editas Medicine, Inc. EDIT|Future Price to Earnings silence-therapeutics.com SLN|PRQR: Price to Future Earnings Ratio|CDXS - Future Price to Earnings|Market Cap to Projected Earnings Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Projected Price to Earnings|Projected Price to Earnings Ratio Metagenomi, Inc. (MGX)|Projected Price to Earnings DTIL|Price to Future Earnings Ratio GBIO (generationbio.com)|Future Price to Earnings Boundless Bio, Inc (BOLD)|Forward P/E Multiple Exicure Inc. (XCUR)|Imunon, Inc. - Projected Price to Earnings|PHIO: Price to Future Earnings Ratio|MBIO - Future Price to Earnings|Price to Expected Earnings Ratio RNAZ|Bionano Genomics, Inc. (BNGO) - Future Price to Earnings|Applied DNA Sciences, Inc. (APDN) - Forward P/E Multiple|BLUE (bluebirdbio.com) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise Antibodies)|Forward P/E Multiple OMGA|Projected Price to Earnings Singular Genomics Systems OMIC|Forward P/E Multiple RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Projected Price to Earnings Ratio|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple